Lysogene’s robust pipeline of therapeutics capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of central nervous system (CNS) diseases. Leveraging the most advanced gene therapy technology and our pioneering research, Lysogene is uniquely positioned to bring safe and effective treatments to market.